FarmavitaR+

1. Pharmaceutical Pricing & Reimbursement in Turkey
(Events/Events)

Pharmaceutical Pricing & Reimbursement in Turkey   Penetrating and optimising market access techniques in a complex and high growth-potential market   22nd September, 2010, Istanbul, Turkey ...

2. Advances in Imaging Biomarkers
(Reports/Market Report)

... is a rapidly growing area in the preclinical development of new pharmaceuticals. Instrumentation to allow CT, PET, SPECT, MRI, ultrasound or optical imaging of small animals is available from a large number ...

3. Clinical Trials 2010
(Events/Events)

... patient recruitment • Conducting clinical trials in emerging economies • E-Clinical trials • Next generation of clinical trials • Impact of credit crunch on the pharmaceutical industry • Optimizing ...

4. How to run the right clinical trials?
(Events/Events)

6th Annual Future of Clinical Trials 26th&27th October 2010, Vienna Leading Pharmaceutical players understand, how to complete trials with greater levels of cost-efficiency, timelines and success.  ...

5. Ukraine in prospect of joining PIC/S
(Regulatory Affairs/Europe not-EU)

... Ministry of Ukraine, Chief State Inspector of Ukraine for Quality Control of Drugs. Pharmaceutical Inspection Cooperation System - PIC / S - an international agreement between national regulatory authorities ...

6. Achieving preferential patient-access through innovative agreements with payers
(Events/Events)

2nd Annual Pharmaceutical Risk-Sharing & Value-Based Pricing & Reimbursement Models 14th-15th September, 2010 Washington DC, USA There is clearly an increasing need for more innovative pricing ...

7. Long-term pricing & reimbursement strategies to penetrate significant growth markets
(Events/Events)

2nd Annual Pharmaceutical Market & Patient Access for Chronic Disease Therapies 15th-16th September, 2010 Brussels, Belgium Chronic diseases are taking a steadily increasing share of national ...

8. Drug Repositioning & R&D Enhancement
(Events/Events)

... and strategic approaches to extend life-cycle management of drug products. Marcus Evans invites senior level executives from pharmaceutical, biotech, and medical device companies to take this opportunity ...

9. Evolution Summit 2010
(Events/Events)

... the leadership of a new bold visionary who will bring fundamental innovation to overhauling the research approaches of the past. When gearing up for the future, pharmaceutical and biopharmaceutical companies ...

10. Pricing and Reimbursement Conference Review
(Pricing and Reimbursment/Pricing and Reimbursment)

Second annual Conference on Pharmaceutical Risk-Sharing  & Value-based Pricing and Reimbursement Models Bratislava, 15-16 th April 2010 Not being a specialist in the area of Risk-Sharing & ...

11. Introduction of Braille script for pharmaceuticals in Ukraine
(Regulatory Affairs/Europe not-EU)

20.05.2009 was introduced an amendment to the law of Ukraine “On medicines” (№ 124/96ВР of 4.04.96) which orders to use Braille script on packages. Changes came into force until 01.01.10. In Ukraine ...

12. Patern Ltd.
(Partners/Regulatory Affairs)

... of the pharmaceutical and health products, equipment and medical devices. Our history includes successful cooperation with companies all over the world: Germany, Austria, Italy, Spain, Poland, Hungary, ...

13. Patern Ltd.
(Partners/Regulatory Affairs)

Patern Ltd. was established in 1998 as a medical market entry company. The main line of activity is outsourcing services for manufacturers, representative offices and distributors of the pharmaceutical ...

14. Emerging Biosimilars Landscape
(Reports/Market Report)

Biosimilars: Key developments in the regulatory environment This report examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the ...

15. Biosimilars: Key developments in the regulatory environment
(Reports/Product Report)

... opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of ...

16. Clinical Trial in India
(Clinical Trilas/Asia)

CLINICAL TRIAL IN INDIA-AN OVERVIEW Global Pharmaceutical companies based in developed countries are increasingly turning to developing countries and emerging economies around the world for conducting ...

17. Standardization of Herbal Drugs
(Professional Articles/Life Science Article)

...  Reproducible efficacy and safety of herbal products is based on reproducible quality. If herbal products are to be regarded as rational drugs, they have to be standardized and their pharmaceutical quality ...

18. Registration of Herbal Medical Products in Albania
(Regulatory Affairs/Europe not-EU)

... traditional substances [e.g. vitamins/minerals which go under the dosage that defines them as medical products and are subject to the pharmaceutical legislation], in the cases when the main active ingredient ...

19. Croatia - Pricing and Reimbursement News
(Pricing and Reimbursment/Pricing and Reimbursment)

... for Health Insurance (HZZO) We suppose that many pharmaceutical manufacturers may not be willing to accept low prices imposed by HZZO and it is not clear about what will happen to manufacturers who does ...

20. Biosimilars expansion in the USA
(Biosimilars/Biosmimilars)

... is set for imminent expansion. Given the size of the US market and the generic erosion which characterizes it, the sector is an attractive prospect for large and established pharmaceutical companies looking ...